ABSTRACT: A novel molecular scaffold has been synthesized and its synthesis and incorporation into new analogues of biologically active molecules will be discussed. A comparison of the inhibitory activity of these compounds to the known type-2 diabetes compound (sitagliptin) against dipeptidyl peptidase-4 (DPP-4) will be shown.
Type-2 diabetes is a chronic disease, characterized by elevated blood sugar levels, leading to severe vascular complications and an increased mortality risk. Dipeptidyl peptidase-4 (DPP-4), a widely distributed serine protease found solubilized in blood or anchored into tissue membranes, is involved in glucose metabolism and is now a validated target for anti-diabetic therapy. Inhibition of DPP-4 has been shown to result in indirect stimulation of insulin secretion. [2] [3] The mechanism of inhibition 4-5 is through an increase in the release of incretin (GLP-1 and GIP) following food intake, therefore inhibiting glucagon release, which in turn increases insulin secretion and decreases blood glucose levels.
6
Sitagliptin (Januvia TM ) was the first approved DPP-4 inhibitor launched by Merck in 2006. The so called "gliptins" are under investigation for other potential therapeutic uses. For example, it was reported that potential substrates of DPP-4 could have implications in other metabolic disorders and that DPP-4 inhibitors could be utilised in the treatment of diseases associated with the immune/inflammatory response, heart failure, cancer and neurodegenerative disorders. In addition it was stated that a positive role of DPP-4 inhibition was observed in diseases of the kidney and the cardiovascular system.
10
In our on-going exploration of novel constrained molecular scaffolds containing substituted ring-fused 1,2,4-triazoles, we were drawn to the possibility of substituting the piperazine-fused 1,2,4-triazolo group present in sitagliptin with a new tricyclic octahydro-[1, 2, 4] To test our hypothesis, preliminary docking studies were carried out with the known crystal structure of sitagliptin in DPP-4 (pdb code 1X70).
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The cis-fused diastereomer 2a (R 2 = CF 3 ) showed a good overlay with sitagliptin as well as a good topographical fit into the enzyme pocket when compared to the trans-fused disatereomer 2b. As expected, the 2, 4, 5-trifluorophenyl group fully occupied the S1 pocket, which was previously reported by the Merck group. 13 From the docking studies it was noted that the key interactions observed in sitagliptin; namely the four hydrogen bond interactions with Tyr662, Glu205 and Glu206 resulting from the (R)-amino group were still preserved along with the water molecule bridge present between the amide carbonyl of 2a with Tyr547. Phe357 provides a ߨ െ ߨ interaction with the triazole core of compound 2a. However, it was noticed that the inclusion of the sterically demanding tricyclic portion of 2a led to a change in the orientation of the CF 3 group, losing the known interaction of this moiety in sitagliptin with Arg358 and Ser209. However, we felt that this potential loss in activity would be compensated by allowing us the exciting potential for discovering new interactions within the DPP-4 protease backbone ( Figure  3 ). The novel scaffold 1 (represented as examples 9a and 9b) was synthesized in a robust six step racemic sequence starting from commercially available ethyl 4-oxopiperidine-1-carboxylate 3. The first step in the sequence was the enamine alkylation with ethyl acrylate under Dean Stark conditions that resulted in a high yield of the -keto ester 4.
14 Conversion of 4 into the O-methyl oxime 5 using methoxyamine hydrochloride in pyridine, delivered the desired compound in a 1:1.5 mixture of imine isomers. These were converted to the bicyclic lactam 6 using Raney Nickel in 7N ammonia in methanol under an atmosphere of hydrogen. At this stage the isomers generated in the ring closure were separated by flash chromatography on silica gel. Unfortunately, no assignment of the ring geometry was possible for the two separated lactam diastereoisomers (7a and 7b) from NMR spectroscopy. Therefore single crystal X-ray crystallography was needed to determine the relative configuration of the two isomers. 15 Each of the isomers (7a and 7b) was converted into their corresponding thiolactams (8a and 8b) using Lawessons' reagent.
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These thiolactams were converted into the corresponding tricyclic triazoles (9a and 9b) by refluxing in toluene with 2,2,2-trifluoroacetohydrazide (Scheme 1). The molecular scaffolds (9a and 9b) were inserted in the sitagliptin structural motif by deprotection of the carbamates (9a and 9b) in ethanol/water using potassium hydroxide under refluxing conditions to afford the key molecular scaffolds (Scheme 1: 1a and 1b, R 1 = H, R 2 = CF3) ready for reaction with the commercially available acids 10 and 11. This coupling was high yielding and the final deprotection to the HCl salts (2a-b and 12a-b) was carried out with 4N HCl in dioxane (Scheme 2). As the synthesis of the scaffolds 9a and 9b was in racemic form, the separation of the diastereoisomers of compounds 2a and 2b was required. Rewardingly, both diastereomers proved separable under chiral HPLC conditions with purity of at least 99% de. Therefore 2a was separated into the single diastereomers (13 and 14) and 2b was separated as single diasteromers (15 and 16) . Due to the robust nature of the synthetic procedure, a small series of further analogues was also produced (examples 17, 18, 19 and 20, see supplementary information for the synthesis and yields). Inhibitory activity against DPP-4 was then determined (Table 1) . Gratifyingly, the compounds demonstrated very good levels of DPP-4 activity when compared to sitagliptin (IC50 22±2 nM). Notably, in all the tested analogues the cis-isomer reproducibly showed a better level of biological activity when compared to the trans-isomer (for example compare 12a and 12b and 17 and 18). As this is an observation throughout all the synthesized derivatives it demonstrates the effect of the connection of the rings to be important to allow the cis-fused compounds to establish optimal interactions within the active site of DPP-4. It was also encouraging to see that the separated diastereoisomers of 2a and 2b were shown to have either a 2.5-fold (cis-isomers, compare compounds 13 and 14) or 3.6-fold (trans-isomers compare compounds 15 and 16) difference in activity, demonstrating further molecular recognition for either the novel cis-fused or trans-fused tricyclic scaffolds within the DPP-4 active site. This was in agreement with our original docking studies (see figure S1 supplementary material) where the 2a cis-isomers (13) (14) were observed to have a better topographical fit into the DPP-4 active site, preserving the water molecule bridge present between the amide carbonyl of 2a with Tyr547. However, from the docking work the 2b trans-isomers (15) (16) were shown to lack this key interaction and, as a consequence, we proposed they would possess lower DPP-4 inhibitory activity.
The enlargement of the CF3 group in 2a to both the ethyl-substituted analogue 17 and the CF2CF3-substituted analogue 19 led to a decrease in inhibitory activity. The lack of the three fluorine atoms in the aromatic region (12a and 12b) substantially decreased the activity, which concurred with similar observations previously reported by the Merck group.
In order to show the influence of the rigid tricyclic ring system towards DPP-4 inhibitory activity, the bicyclic compound 24 was synthesized. The commercially available amine 21 was converted to the substituted 1,2,4 triazole 23 in 15% yield.
19 Final deprotection of the carbamate group in 23 was carried out under established standard conditions using KOH in water/ethanol and the coupling to the final bicyclic compound 24 was achieved using acid 11, followed by deprotection using 4N HCl in dioxane (Scheme 3). In order to gain insight into the impact of ring size for DPP-4 inhibitory activity, the synthesis of the novel cisfused hexahydro-6H-[1,2,4]triazolo[4',3':1,5]pyrrolo[3,2-c]pyridine analogue 31 was carried out. The synthesis to the 5-membered lactams (28 and 29) followed a slightly different approach than for the 6, 6-membered lactams 7a-b. Commercially available ethyl 4-oxopiperidine-1-carboxylate 3 was converted into tert-butylester 25 using LDA and tert-butyl 2-bromoacetate. The tert-butylester 25 was converted through to the substituted benzylamine 26 via a reductive amination reaction using benzylamine and sodium triacetoxyborohydride in 1,2-dichloroethane. Compound 26 was trans-esterified with 0.6M HCl in methanol to yield the methyl ester 27, which was catalytically-hydrogenated using Pd/C in MeOH under an atmosphere of hydrogen. The final ring closure to the key bicyclic lactams 28 and 29 was carried out with potassium carbonate in methanol and the diastereomers were separated by flash column chromatography. Once more structural determination of the separated diastereomers (28 1nd 29) was performed through X-ray crystallography [see reference 15] (Scheme 4). The separated cis-fused isomer 29 was converted through to the final product through the standard synthetic procedure (Scheme 5). The DPP-4 inhibitory activity for compounds 24 (IC50 100±4 nM) and 31 (IC50 94±4 nM) was established showing a reduced level of activity compared to 13 (separated most active isomer of compound 2a, IC50 28±1 nM). In order to understand the DPP-4 inhibitory activity of compounds 2a, 24 and 31, the compounds were energy minimized and docked into the known crystal structure of sitagliptin in DPP-4. As previously mentioned, compound 2a displayed a good topographical fit into the enzyme pocket, whereas compound 31 docked to allow overlay of the trifluoromethyl group of 31 with that of sitagliptin. However, in achieving this topographical fit, the Phe357 π-π interaction with the triazole core of compound 31 is lost due to a steric clash imposed by the rigid tricyclic ring system and this could be an explanation for the observed loss in DPP-4 inhibitory potency of 31 when compared to 2a. For the bicyclic compound 24, once more there is a good topographical fit into the enzyme pocket, however the Phe357 π-π interaction with the triazole core of compound 24 is not present and this could again be an explanation for the observed loss in DPP-4 inhibitory potency (Figure 4 ). 6] naphthyridine tricyclic ring system and we are currently investigating a chiral synthesis of the key intermediates along with further structure design-based synthesis of analogues to interrogate the SAR within this interesting new tricyclic scaffold which we will report in due course.
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